Today’s Research Reports on Trending Tickers: Vericel Corporation and RXi Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched a low of 23,523.16 before settling at 24,264.30, an increase of 0.96 percent, while the S&P 500 Index hit a low of 2,573.61 before rallying to close at 2,644.69, an increase of 1.16 percent. The tech-heavy Nasdaq Composite Index reached a low of 6,811.77 before settling to close at 7,042.11, an increase of 1.45 percent.
"The prospects for a trade war are there, investors are just not sure how to assess the impact that could come. This brings in an incredible amount of uncertainty, but people may just respond to things as they unfold," said Michael O'Rourke, chief market strategist at JonesTrading, according to MarketWatch.
RDI Initiates Coverage on:
Vericel Corporation
https://rdinvesting.com/news/?ticker=VCEL
RXi Pharmaceuticals Corp.
https://rdinvesting.com/news/?ticker=RXII
Vericel's stock jumped 15.54% Wednesday, to close the day at $11.15. The stock recorded a trading volume of 1,885,705 shares, which was above its three months average volume of 1,000,608 shares. In the last year, Vericel's shares have traded in a range of 2.35 - 12.80. The share price has gained 374.47% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $9.64 is greater than its 200-day moving average of $6.37. Shares of Vericel have gained roughly 33.53 percent in the past month and are up 104.59 percent year-to-date.
Access RDI's Vericel Corporation Research Report at:
https://rdinvesting.com/news/?ticker=VCEL
On Wednesday, shares of RXi Pharmaceuticals recorded a trading volume of 2,936,314 shares, which was above the three months average volume of 297,398 shares. The stock ended the day 24.91% higher at 3.31. The share price has gained 31.87% from its 52-week low with a 52-week trading range of 2.51 - 8.30. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.53 is below its 200-day moving average of $4.81. Shares of RXi Pharmaceuticals have gained roughly 22.59 percent in the past month and are down 40.47 percent year-to-date.
Access RDI's RXi Pharmaceuticals Corp. Research Report at:
https://rdinvesting.com/news/?ticker=RXII
Our Actionable Research on Vericel Corporation (NASDAQ:VCEL) and RXi Pharmaceuticals Corp. (NASDAQ:RXII) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
